Tuberc Respir Dis.  2023 Jan;86(1):1-13. 10.4046/trd.2022.0066.

New Targeted Therapy for Non-Small Cell Lung Cancer

• Chung EK
• Yong SH
• Lee EH
• Kim EY
• Chang YS
• Lee SH

• KMID: 2537198
• DOI: http://doi.org/10.4046/trd.2022.0066

Abstract

Lung cancer ranks first in cancer mortality in Korea and cancer incidence in Korean men. More than half of Korean lung cancer patients undergo chemotherapy, including adjuvant therapy. Cytotoxic agents, targeted therapy, and immune checkpoint inhibitors are used in chemotherapy according to the biopsy and genetic test results. Among chemotherapy, the one that has developed rapidly is targeted therapy. The National Comprehensive Cancer Network (NCCN) guidelines have been updated recently for targeted therapy of multiple gene mutations, and targeted therapy is used not only for chemotherapy but also for adjuvant therapy. While previously targeted therapies have been developed for common genetic mutations, recently targeted therapies have been developed to overcome uncommon mutations or drug resistance that have occurred since previous targeted therapy. Therefore, this study describes recent, rapidly developing targeted therapies.

Keyword

Carcinoma, Non-Small-Cell Lung; Molecular Targeted Therapy; Prognosis